Persistently Elevated Glucagon-Like Peptide-1 Levels among Critically Ill Surgical Patients after Sepsis and Development of Chronic Critical Illness and Dismal Long-Term Outcomes.

[1]  B. Brumback,et al.  The Development of Chronic Critical Illness Determines Physical Function, Quality of Life, and Long-Term Survival Among Early Survivors of Sepsis in Surgical ICUs* , 2019, Critical care medicine.

[2]  H. Baker,et al.  Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery. , 2018, Surgery.

[3]  L. Moldawer,et al.  Chronic Critical Illness and the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome , 2018, Front. Immunol..

[4]  B. Brumback,et al.  Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness after sepsis in surgical intensive care unit patients , 2017, The journal of trauma and acute care surgery.

[5]  C. Dejong,et al.  Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion. , 2017, Cell reports.

[6]  F. Tacke,et al.  GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease. , 2017, The American journal of medicine.

[7]  B. Brumback,et al.  Sepsis and Critical Illness Research Center investigators: protocols and standard operating procedures for a prospective cohort study of sepsis in critically ill surgical patients , 2017, BMJ Open.

[8]  L. Moldawer,et al.  Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome , 2017, Critical care medicine.

[9]  A. Gabrielli,et al.  Computer versus paper system for recognition and management of sepsis in surgical intensive care , 2014, The journal of trauma and acute care surgery.

[10]  R. S. Smith,et al.  Mild hyperglycemia, but not glucagon-like peptide 1 predicts poor outcome after injury. , 2012, American journal of surgery.

[11]  L. Moldawer,et al.  Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.

[12]  Steven B. Johnson,et al.  Effect of Glycemic State on Hospital Mortality in Critically Ill Surgical Patients , 2011, The American surgeon.

[13]  M. Gassmann,et al.  Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells , 2011, Nature Medicine.

[14]  T. Scalea,et al.  Glucose elevations and outcome in critically injured trauma patients. , 2011, Advances in surgery.

[15]  B. McKinley,et al.  Computer protocol facilitates evidence-based care of sepsis in the surgical intensive care unit. , 2011, The Journal of trauma.

[16]  J. Wishart,et al.  Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes , 2011, Critical care.

[17]  Robert W. Koernig,et al.  Gender Differences in Glucose Variability after Severe Trauma , 2010, The American surgeon.

[18]  Karen L Jones,et al.  Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: Relationship to glycemia* , 2010, Critical care medicine.

[19]  D. Andersen,et al.  Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. , 2009, The Journal of clinical endocrinology and metabolism.

[20]  M. Horowitz,et al.  The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study , 2009, Critical care.

[21]  Renda Soylemez Wiener,et al.  Ill Adults: A Meta-analysis Benefits and Risks of Tight Glucose Control in Critically , 2010 .

[22]  Hanqing Cao,et al.  Blood Glucose Variability is Associated with Mortality in the Surgical Intensive Care Unit , 2008, The American surgeon.

[23]  G. Van den Berghe,et al.  Tight blood glucose control: What is the evidence? , 2007, Critical care medicine.

[24]  T. Scalea,et al.  Admission hyperglycemia is predictive of outcome in critically ill trauma patients. , 2005, The Journal of trauma.

[25]  B. Göke,et al.  Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans , 2005, Gut.

[26]  M. Nauck,et al.  Glucagon-like peptide 1 and its derivatives in the treatment of diabetes , 2005, Regulatory Peptides.

[27]  Steven B Johnson,et al.  Persistent hyperglycemia is predictive of outcome in critically ill trauma patients. , 2005, The Journal of trauma.

[28]  G. Bochicchio,et al.  Admission Preoperative Glucose is Predictive of Morbidity and Mortality in Trauma Patients who Require Immediate Operative Intervention , 2005, The American surgeon.

[29]  J Wayne Meredith,et al.  Relationship of early hyperglycemia to mortality in trauma patients. , 2004, The Journal of trauma.

[30]  G. Tinkoff,et al.  Admission hyperglycemia as a prognostic indicator in trauma. , 2003, The Journal of trauma.

[31]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[32]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[33]  Miet Schetz,et al.  Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control* , 2003, Critical care medicine.

[34]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[35]  G. V. Berghe,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[36]  A. Joyner,et al.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene , 1996, Nature Medicine.

[37]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[38]  C. Saper,et al.  Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. , 2002, The Journal of clinical investigation.